Welcome to our dedicated page for Dbv Technologies S A news (Ticker: DBVT), a resource for investors and traders seeking the latest updates and insights on Dbv Technologies S A stock.
DBV Technologies S.A. develops treatment options for food allergies and other immunologic conditions as a late-stage biopharmaceutical company. Company updates center on the proprietary VIASKIN® patch technology, epicutaneous immunotherapy, and the VIASKIN Peanut program for peanut-allergic toddlers and children.
Recurring developments include clinical data from the Phase 3 VITESSE study, annual and quarterly financial results, financing and warrant-related capital actions, leadership and governance changes, share and voting-rights disclosures under French market rules, and market information tied to DBVT American Depositary Shares.
DBVT (NYSE Euronext Paris, ISIN: FR0010417345) announced the total number of shares and voting rights as of December 31, 2025 in accordance with Article 223-16 of the AMF General Regulations.
The company reported a total number of shares of 232,207,589, a total gross of voting rights of 232,207,589, and a total net of voting rights of 232,133,009 (net excludes shares without voting rights). A PDF attachment is available for the detailed statement.
DBV Technologies (Nasdaq:DBVT) announced positive topline Phase 3 VITESSE results for the VIASKIN Peanut patch in children aged 4–7. The trial met its primary endpoint: 46.6% responder rate on active vs 14.8% on placebo (difference 31.8%; 95% CI 24.5–39.0%; lower bound >15%; p=1x10-17). VITESSE enrolled 654 children (438 active, 216 placebo). Safety was consistent with prior studies: no treatment-related serious adverse events, 0.5% treatment-related anaphylaxis (n=2), discontinuations 3.2% active vs 0.5% placebo, and compliance 96.2%. A U.S. BLA submission in H1 2026 is on track. Positive topline results accelerate exercise of warrants, now exercisable through Jan 15, 2026.
Company (NYSE:DBVT) reports the total number of shares and voting rights as of November 30, 2025 under Article 223-16 of the AMF General Regulations.
As of 11/30/2025 the total number of shares is 200,777,718. The total gross voting rights equals 200,777,718 and the total net voting rights is 200,667,869 (net total excludes shares without voting rights). ISIN: FR0010417345.
DBV Technologies (NASDAQ:DBVT) announced completion of the last patient visit in the VITESSE Phase 3 trial of the VIASKIN® Peanut patch in peanut-allergic children aged 4–7 years. The double-blind, placebo-controlled treatment phase is complete and the company remains on track to report topline data in Q4 2025.
The 12-month study enrolled 654 subjects randomized 2:1 across 86 sites in the U.S., Canada, Europe, the UK, and Australia. DBV described VITESSE as the largest treatment intervention study in peanut allergy and thanked investigators, patients, and caregivers for participation.
DBV Technologies (Nasdaq: DBVT) announced that Daniel Tassé, Chief Executive Officer, will participate in a fireside chat at the Guggenheim 2nd Annual Healthcare Innovation Conference on Tuesday, November 11, 2025 at 2:00 p.m. ET in Boston, Massachusetts.
A live webcast will be available via the company’s Events page and an archived replay will be accessible for 90 days after the event. The presentation offers investors a direct opportunity to hear management remarks and strategic commentary.
DBV Technologies (Nasdaq: DBVT) appointed Kevin Trapp as Chief Commercial Officer, effective November 3, 2025, to lead global commercial strategy for the Viaskin® Peanut patch. DBV expects VITESSE Phase 3 topline results in Q4 2025 and plans a BLA submission for ages 4–7 in H1 2026, followed by a BLA submission for ages 1–3 in H2 2026. Mr. Trapp has 30+ years in biopharma and previously consulted for DBV since 2017.
DBVT (NYSE Euronext Paris, ISIN FR0010417345) disclosed its total number of shares and voting rights as of October 31, 2025. The company reported a total number of shares of 179,827,919.
The total gross voting rights equals 179,827,919 and the total net voting rights (excluding shares without voting rights) equals 179,741,847.
This information is provided under Article 223-16 of the General Regulations of the Autorité des Marchés Financiers and was communicated on November 3, 2025.
DBV Technologies (Nasdaq:DBVT) announced the provisional appointment of Philina Lee, Ph.D. to its Board of Directors, effective October 30, 2025. She replaces Daniel Soland and will serve on the Board's Compensation Committee, increasing the Board to ten directors. The appointment is provisional and subject to shareholder ratification at the next annual meeting. Dr. Lee joins from Blueprint Medicines, where she led commercial operations including the launch and growth of AYVAKIT, and previously served on Fusion Pharmaceuticals' Board committees. DBV said her commercial and product-launch experience is expected to support advancement toward potential commercialization of VIASKIN Peanut for children and toddlers.
DBV Technologies (Nasdaq: DBVT) will participate in the ACAAI 2025 Annual Scientific Meeting in Orlando, November 6–10, 2025. DBV will host a Product Theater on Nov 8, 2025 (11:35 a.m.–1:00 p.m. ET) titled “Harnessing Immune Plasticity to Alter the Path of Food Allergy.”
The presentation will include a panel of allergists and details of a planned Phase 2 study assessing VIASKIN Peanut patch efficacy and safety to achieve ad lib peanut consumption in infants aged 6–12 months after a minimum of 3 years of treatment. Dr. Matthew Greenhawt will present EPOPEX end-of-study results on Nov 8 at 4:43 p.m. ET.
DBV will exhibit at booth #711, sponsor the FIT Bowl on Nov 8 (5:45–7:45 p.m. ET), and notes line-of-sight to a potential BLA filing for toddlers 1–3 years in the second half of next year under an Accelerated Approval Pathway.
DBV Technologies (Nasdaq: DBVT) announced an at-the-market sale of ADSs on October 29, 2025, raising approximately $30 million gross through Artisan via Citizens Capital Markets.
The transaction issues 2,142,860 ADSs (representing 10,714,300 ordinary shares), priced at $14.00 per ADS (subscription price €2.4063), and is expected to settle on October 31, 2025. New shares represent 6.34% of existing Euronext-listed shares and dilute existing holders by ~5.96%. Management estimates cash runway extended to end of Q4 2026; topline pediatric results and BLA timing reiterated for 4Q2025–1H/2H2026.